ULTIMOVACS ASA (ULTI.OL) Stock Price & Overview
OSL:ULTI • NO0010851603
Current stock price
The current stock price of ULTI.OL is 2.11 NOK. Today ULTI.OL is down by -3.21%. In the past month the price increased by 1.44%. In the past year, price decreased by -73.62%.
ULTI.OL Key Statistics
- Market Cap
- 426.79M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.81
- Dividend Yield
- N/A
ULTI.OL Stock Performance
ULTI.OL Stock Chart
ULTI.OL Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ULTI.OL. When comparing the yearly performance of all stocks, ULTI.OL is a bad performer in the overall market: 96.09% of all stocks are doing better.
ULTI.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ULTI.OL. ULTI.OL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ULTI.OL Earnings
ULTI.OL Forecast & Estimates
9 analysts have analysed ULTI.OL and the average price target is 6.29 NOK. This implies a price increase of 198.11% is expected in the next year compared to the current price of 2.11.
ULTI.OL Groups
Sector & Classification
ULTI.OL Financial Highlights
Over the last trailing twelve months ULTI.OL reported a non-GAAP Earnings per Share(EPS) of -5.81. The EPS decreased by -5.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -173.53% | ||
| ROE | -243.21% | ||
| Debt/Equity | 0 |
ULTI.OL Ownership
ULTI.OL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.71 | 42.625B | ||
| 1AE | ARGENX SE | 29.52 | 42.6B | ||
| 22UA | BIONTECH SE-ADR | N/A | 23.126B | ||
| ABVX | ABIVAX SA | N/A | 7.766B | ||
| 2X1 | ABIVAX SA | N/A | 7.747B | ||
| GLPG | GALAPAGOS NV | N/A | 1.629B | ||
| GXE | GALAPAGOS NV | N/A | 1.628B | ||
| NANO | NANOBIOTIX | N/A | 1.392B | ||
| PHARM | PHARMING GROUP NV | 46.9 | 1.025B | ||
| PHGN | PHARMING GROUP NV | 47.72 | 1.021B | ||
| 6IV | INVENTIVA SA | N/A | 990.777M | ||
| IVA | INVENTIVA SA | N/A | 934.695M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 932.473M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Oslo Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About ULTI.OL
Company Profile
Ultimovacs AS operates as a pharmaceutical company. The company is headquartered in Oslo, Oslo and currently employs 17 full-time employees. The company went IPO on 2019-06-03. Ultimovacs’ technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital. Ultimovacs is advancing a broad clinical development program with clinical trials in Europe, Australia and the U.S. The firm's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action.
Company Info
IPO: 2019-06-03
ULTIMOVACS ASA
Ullernchausseen 64
Oslo OSLO NO
Employees: 23
Phone: 4741380080
ULTIMOVACS ASA / ULTI.OL FAQ
What does ULTIMOVACS ASA do?
Ultimovacs AS operates as a pharmaceutical company. The company is headquartered in Oslo, Oslo and currently employs 17 full-time employees. The company went IPO on 2019-06-03. Ultimovacs’ technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital. Ultimovacs is advancing a broad clinical development program with clinical trials in Europe, Australia and the U.S. The firm's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action.
What is the stock price of ULTIMOVACS ASA today?
The current stock price of ULTI.OL is 2.11 NOK. The price decreased by -3.21% in the last trading session.
Does ULTI stock pay dividends?
ULTI.OL does not pay a dividend.
What is the ChartMill technical and fundamental rating of ULTI stock?
ULTI.OL has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is ULTIMOVACS ASA (ULTI.OL) stock traded?
ULTI.OL stock is listed on the Euronext Oslo exchange.
Can you provide the sector and industry classification for ULTIMOVACS ASA?
ULTIMOVACS ASA (ULTI.OL) operates in the Health Care sector and the Biotechnology industry.
Would investing in ULTIMOVACS ASA be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ULTI.OL.